The prognostic importance of triple negative breast carcinoma

被引：112

作者：

Mersin, Hakan ^{[1
]}

Yildirim, Emin ^{[1
]}

Berberoglu, Ugur ^{[1
]}

Guelben, Kaptan ^{[1
]}

机构：

[1] Ankara Oncol Training & Res Hosp, Dept Surg, Ankara, Turkey

来源：

BREAST | 2008年 / 17卷 / 04期

关键词：

breast carcinoma; triple negative; HER2; ER; PR;

D O I：

10.1016/j.breast.2007.11.031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is a current debate on whether triple negative breast carcinomas (estrogen receptor - ER-negative, progesterone receptor - PR-negative and HER2-negative) have a poor prognosis. Our aim in this retrospective study was to determine whether triple negative tumor histology. In the multivariate analysis, tumor subgroup (triple, p < 0.0001; hazard ratio [HR], 4.2; 95% confidence interval [95%CI], 2.2-8.2) was a significant factor related to relapse, in addition to number of metastatic nodes (> 4 vs <= 4, p = 0.04; HR, 1.6; 95%CI,1.2-2.4), lymphatic vascular invasion (yes vs no. p = 0.002; HR, 2.0; 95%CI, 1.3-3.1) and HER2 (positive vs negative, p < 0.0001; HR, 5.9; 95%CI, 3.0-10.0). This result indicated that patients with triple negative histology had a poor disease-free survival and this histology was an independent significant prognostic factor for DFS. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：341 / 346

页数：6

共 25 条

[1] Basal-like breast carcinomas: clinical outcome and response to chemotherapy [J].

Banerjee, S. ;

Reis-Filho, J. S. ;

Ashley, S. ;

Steele, D. ;

Ashworth, A. ;

Lakhani, S. R. ;

Smith, I. E. .

JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) :729-735

[2] HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].

BLOOM, HJG ;

RICHARDSON, WW .

BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&

[3] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].

Carey, Lisa A. ;

Perou, Charles M. ;

Livasy, Chad A. ;

Dressler, Lynn G. ;

Cowan, David ;

Conway, Kathleen ;

Karaca, Gamze ;

Troester, Melissa A. ;

Tse, Chiu Kit ;

Edmiston, Sharon ;

Deming, Sandra L. ;

Geradts, Joseph ;

Cheang, Maggie C. U. ;

Nielsen, Torsten O. ;

Moorman, Patricia G. ;

Earp, H. Shelton ;

Millikan, Robert C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502

[4] Prognostic and predictive factors in early-stage breast cancer [J].

Cianfrocca, M ;

Goldstein, LJ .

ONCOLOGIST, 2004, 9 (06) :606-616

[5]

COX DR, 1972, J R STAT SOC B, V34, P187

[6] Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 [J].

Goldhirsch, A ;

Glick, JH ;

Gelber, RD ;

Coates, AS ;

Thürlimann, B ;

Senn, H ;

Albain, KS ;

Bergh, J ;

Castiglione-Gertsch, M ;

Coates, AS ;

Costa, A ;

Cuzick, J ;

Davidson, N ;

Forbes, JF ;

Gelber, RD ;

Goss, P ;

Harris, J ;

Glick, JH ;

Goldhirsch, A ;

Howell, A ;

Ingle, JN ;

Jakesz, R ;

Jassem, J ;

Kaufmann, M ;

Martin, M ;

Mauriac, L ;

Morrow, M ;

Mouridsen, HT ;

Namer, M ;

Piccart-Gebhart, MJ ;

Possinger, K ;

Pritchard, K ;

Rutgers, EJT ;

Thürlimann, B ;

Viale, G ;

Wallgren, A ;

Wood, WC .

ANNALS OF ONCOLOGY, 2005, 16 (10) :1569-1583

[7]

Greene FL., 2002, AJCC CANC STAGING HD, V6th

[8] Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer [J].

Haffty, Bruce G. ;

Yang, Qifeng ;

Reiss, Michael ;

Kearney, Thomas ;

Higgins, Susan A. ;

Weidhaas, Joanne ;

Harris, Lyndsay ;

Hait, Willam ;

Toppmeyer, Deborah .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5652-5657

[9] Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study:: assessment of test sensitivity and impact of chromosome 17 polysomy [J].

Hofmann, M. ;

Stoss, O. ;

Gaiser, T. ;

Kneitz, H. ;

Heinmoeller, P. ;

Gutjahr, T. ;

Kaufmann, M. ;

Henkel, T. ;

Rueschoff, J. .

JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (01) :89-94

[10] Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer [J].

Huang, HJ ;

Neven, P ;

Drijkoningen, M ;

Paridaens, R ;

Wildiers, H ;

Van Limbergen, E ;

Berteloot, P ;

Amant, F ;

Vergote, I ;

Christiaens, MR .

JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (06) :611-616

← 1 2 3 →